Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Novartis May Sell US Generic Pill Business 19
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21
Venture Financing 22
Ambrx Raises USD45 Million in Venture Financing 22
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
Private Equity 26
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26
Partnerships 27
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29
Kite Pharma Forms Joint Venture with Fosun Pharma 30
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 32
Nature’s Sunshine Products Forms Joint Venture with Fosun Pharma 33
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35
Atrium Innovations Forms Joint Venture With Fosun Industrial 36
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39
Licensing Agreements 40
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial – Portela 40
Athenex to Enter into Licensing Agreement with Gland Pharma 41
Athenex to Enter into Licensing Agreement with Gland Pharma 42
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43
Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47
Equity Offering 48
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48
Gland Pharma May Raise USD500 Million in IPO 50
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51
Chindex to Raise USD38.2 Million in Private Placement of Shares 53
Phagelux Raises Funds through Private Placement 54
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58
Nature’s Sunshine Raises USD46 Million in Private Placement of Shares 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 61
Debt Offering 62
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68
Asset Transactions 69
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69
Acquisition 70
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 78
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 79
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Competitors 87
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Employees 88
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Recent Developments 91
Strategy And Business Planning 91
Nov 15, 2017: Fosun Pharma set up Suzhou R & D Center 91
Jul 11, 2017: Rooted in Shanghai innovation Fosun Pharma Zhangjiang new R & D headquarters base was officially launched 92
Financial Announcements 94
Mar 27, 2018: Fosun pharma: Announcement of Final Results for the Year Ended 31 December 2017 94
Oct 31, 2017: Fosun Pharma releases third quarter 2017 revenue up 21.83% YoY Research and development investment continues to increase 96
Aug 30, 2017: Fosun Pharma: R & D and international lighting performance, the first half revenue grew 20.41% 97
Jun 14, 2017: Fosun Pharma released first quarter 2017 revenue up 20.29% R & D investment continued to increase 99
Mar 31, 2017: Fosun Pharma non-net profit in 2016 increased by 26.36% year-on-year Continued to increase innovation and R & D investment Strengthen the layout of medical services 100
Corporate Communications 103
Mar 26, 2018: Change In Fosun Pharma’s Board Of Directors To Further Align Group Strategy 103
Mar 26, 2018: Shanghai Fosun Pharmaceutical Announces Personnel Changes 104
Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World’s Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 106
Product Approvals 108
Oct 29, 2017: Fosun Pharma treatment of leukemia new drug approved by the FDA drug clinical trials 108
Appendix 109
Methodology 109
About GlobalData 109
Contact Us 109
Disclaimer 109
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Novartis May Sell US Generic Pill Business 19
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21
Ambrx Raises USD45 Million in Venture Financing 22
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29
Kite Pharma Forms Joint Venture with Fosun Pharma 30
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 32
Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 33
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35
Atrium Innovations Forms Joint Venture With Fosun Industrial 36
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial - Portela 40
Athenex to Enter into Licensing Agreement with Gland Pharma 41
Athenex to Enter into Licensing Agreement with Gland Pharma 42
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43
Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48
Gland Pharma May Raise USD500 Million in IPO 50
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51
Chindex to Raise USD38.2 Million in Private Placement of Shares 53
Phagelux Raises Funds through Private Placement 54
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58
Nature's Sunshine Raises USD46 Million in Private Placement of Shares 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 61
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 78
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 79
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Competitors 87
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Employees 88
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Subsidiaries 90
List of Figures
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13